Glucocemin

Glucocemin is a prescription‑only solution for injection that contains glucose monohydrate as its active ingredient. The product is supplied in an aqueous solution intended for intravenous administration. Marketed in the European Union, Glucocemin provides a readily available source of glucose for patients requiring parenteral nutrition, treatment of hypoglycemia, or fluid and electrolyte replacement. It is classified as an excipient in the parenteral nutrition therapeutic class.

Glucocemin is indicated for several clinical situations where rapid glucose supplementation is needed. It is commonly employed in hospital and critical‑care settings to address metabolic and fluid requirements.

- Treatment of acute hypoglycemia in adults and children - Component of parenteral nutrition regimens for patients unable to receive enteral feeding - Fluid and electrolyte replacement during surgery or trauma care - Provision of caloric energy during prolonged fasting or intensive care - Maintenance of glucose levels in neonatal intensive care units - Support for patients with malnutrition or severe catabolic states

Glucocemin may cause a range of adverse reactions, most of which are related to its glucose content and intravenous delivery.

Common: - Transient hyperglycemia - Local irritation or phlebitis at the infusion site - Mild nausea or vomiting - Headache - Electrolyte disturbances such as hypokalemia - Fluid overload in susceptible patients

Serious: - Severe hyperglycemia leading to osmotic diuresis - Anaphylactic or severe allergic reaction - Metabolic acidosis - Significant fluid overload causing pulmonary edema - Severe electrolyte imbalance (e.g., hypernatremia) - Life‑threatening hypoglycemia when combined with insulin overdose

When using Glucocemin, clinicians should observe several safety measures to minimize risks. Patient assessment and monitoring are essential throughout therapy.

- Monitor blood glucose levels frequently and adjust infusion rates accordingly - Assess renal and hepatic function before initiating therapy - Use caution in patients with known glucose intolerance or uncontrolled diabetes - Observe for signs of fluid overload, especially in heart‑failure patients - Ensure compatible IV lines and aseptic technique to prevent infection - Adjust electrolyte supplementation as needed during prolonged infusion - Discontinue or reduce dose if severe hyperglycemia or adverse reactions occur

Glucocemin can interact with other medications and solutions administered intravenously. Awareness of these interactions helps prevent complications.

Avoid: - Concurrent high‑dose insulin therapy without close glucose monitoring - Simultaneous infusion of other hyperosmolar dextrose solutions that may cause fluid overload - Use with medications that markedly increase blood glucose (e.g., high‑dose corticosteroids) without adjusting dose

Use with caution: - Catecholamines and beta‑adrenergic agonists that can affect glucose metabolism - Diuretics that may alter electrolyte balance - Other parenteral nutrition components requiring careful osmolarity management - Medications that may cause hypokalemia, requiring electrolyte monitoring - Drugs with known hypersensitivity potential in patients with a history of allergic reactions